About OUR JOINT RESEARCH INITIATIVE

The Berlin-Dresden MASLD Joint Research Initiative seeks to address the pressing need to find effective treatment options for  Metabolic dysfunction-associated steatotic liver disease (MASLD). Several recently failed clinical trials have set back the MASLD field and have made it evident that the concept of “one fits all” therapy may not be suitable for the multiple and heterogeneous disease-driving mechanisms in  patients suffering from NAFLD. Hence, an entirely fresh look to MASLD pathogenesis and therapeutic approach is required, which has motivated us to form a new center, composed of basic and clinical investigators with expertise in metabolism, immunology, fibrosis and systems biology.  Our initiative includes investigators from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH, Berlin),  from Technische Universität Dresden  and the  Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBP, Dresden) as well as from the